Endometrial angiogenic response in Norplant users.
The levonorgestrel-releasing subdermal contraceptive implant Norplant is well accepted among Indonesian users, despite the problems with irregular and prolonged menstrual bleeding. Bleeding can be the major reason for women discontinuing their use of Norplant. The causes of endometrial bleeding may include disturbances in endometrial regeneration and angiogenesis. The aim of this study was to investigate endometrial angiogenic activity in Norplant users and to compare it to that in the normal menstrual cycle. The study also aimed to determine the correlation between endometrial angiogenic activity and plasma concentrations of oestradiol, progesterone, sex hormone binding globulin and levonorgestrel, as well as the free levonorgestrel index. The subjects for this study were selected from Norplant users with an exposure of between 3 and 12 months. Endometrial angiogenic response was assayed using an endothelial cell migration assay. Six blood samples to monitor oestradiol and progesterone concentrations were taken during the 2 weeks prior to endometrial biopsy. Samples for the analysis of sex hormone binding globulin and levonorgestrel were taken on the day of biopsy. The results showed that the median score of endometrial angiogenic activity in the 30 women used as controls were significantly higher than the 40 Norplant acceptors (z = -3.80, one tail, P < 0.001). There was no significant correlation between the endothelial migration score and peripheral hormonal concentrations or the free levonorgestrel index in Norplant users. There was no difference in the endometrial angiogenic activity in endometrium with and without bleeding problems. However, it is interesting to note that four Norplant acceptors who had an endothelial cell migration score > or = 1.0 had the lowest free levonorgestrel index.
Subakir
S B
SB
Department of Physiology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Hadisaputra
W
W
Handoyo
A E
AE
Affandi
B
B
D000293:Adolescent; D000328:Adult; D001681:Biological Assay; D001706:Biopsy; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003271:Contraceptive Agents, Female / Q000097:blood / Q000494:pharmacology*; D004717:Endometrium / Q000166:cytology* / Q000473:pathology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000097:blood / Q000494:pharmacology*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D009924:Organ Culture Techniques; D011374:Progesterone / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D014592:Uterine Hemorrhage / Q000097:blood* / Q000145:classification / Q000503:physiopathology
D003271:Contraceptive Agents, Female; D012738:Sex Hormone-Binding Globulin; D011374:Progesterone; D004958:Estradiol; D016912:Levonorgestrel